Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL125892, F30HL134252, R01HL125892)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM07205, T32GM07205, 5T32GM007223-43)
Received: 6 October 2017
Accepted: 30 May 2018
First Online: 26 June 2018
: R.B., P.M.G., E.Q., A.S.R., D.H.S., D.H.L., and W.M.S. are inventors on patent applications describing nanoparticle-mediated delivery of triplex-forming PNAs for gene editing. W.M.S., D.H.S., J.S.F., A.S.R, and A.H.B. are inventors on a patent application for in utero therapies using particles for protein delivery. D.H.L. and R.B. are inventors on a patent application regarding the synthesis of γPNAs. These patents have been licensed to Trucode Gene Repair, Inc., San Francisco, CA. P.M.G. and W.M.S. are consultants for and have equity interests in Trucode Gene Repair, Inc. The remaining authors declare no competing interests.